These two drugs contributed to Novo's sales, but as can be seen in the above chart they ... dosing and presents another risk to the long-term sustainability of Novo's GLP-1 sales.

Unplanned pregnancies are still being reported among people using GLP-1 drugs, but now fertility specialists are ...

Analyzing H&H's Q3 results and investment strategy in the healthcare industry, highlighting undervaluation and raising the ...

The drug maker has seen strong success in recent years ... Mounjaro & Zepbound: Key Top-Line Drivers for Lilly Tirzepatide is ...

In return for his backing when Kennedy largely dropped his independent presidential bid, Trump has said he would allow Kennedy "to run wild" on healthcare, without offering details.

The drug industry witnessed major policy changes during Joe Biden's four-year term as U.S. President, including the historic ...

A mum is warning people not to take skinny jabs from 'strangers on the internet' - after nearly dying when she accidentally injected 'five times' the recommended dose sent as a 'freebie' over ...

The FDA updated GLP-1 drug labels to warn of the risk of patients breathing food into their lungs while under anesthesia for ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new recommendations.

Despite their benefits, access to GLP-1 medications remains inequitable. Perceived high costs, inconsistent insurance ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

Low-income patients' access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found.